Preclinical and Clinical Antiviral Characterization of AB-836, a Potent Capsid Assembly Modulator Against Hepatitis B Virus.
AB-836
antiviral therapy
capsid assembly modulator
chronic hepatitis B
polymorphism
resistance
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
24 Sep 2024
24 Sep 2024
Historique:
received:
16
08
2024
revised:
11
09
2024
accepted:
23
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
26
9
2024
Statut:
aheadofprint
Résumé
HBV capsid assembly modulators (CAMs) target the core protein and inhibit pregenomic RNA encapsidation and viral replication. HBV CAMs also interfere with cccDNA formation during de novo infection, which in turn suppresses transcription and production of HBV antigens. In this report, we describe the antiviral activities of AB-836, a potent and highly selective HBV CAM. AB-836 inhibited viral replication (EC
Identifiants
pubmed: 39326502
pii: S0166-3542(24)00219-5
doi: 10.1016/j.antiviral.2024.106010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106010Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: